The latest price announcement in 2024: The listing price of avatrombopag is freshly released!

Avatrombopag (Avatrombopag) is an oral drug that belongs to the thrombopoietin receptor agonist (TPO receptor agonist) class of drugs. Its mechanism of action is by stimulating platelet production in the bone marrow, thereby increasing platelet numbers. Avatrombopag is primarily used to treat adults with chronic idiopathic thrombocytopenia (ITP).

Avatrombopag is now on the market in China and has been successfully included in medical insurance. Patients can purchase it directly in China at a price of about three to four thousand yuan. For specific costs and medical insurance reimbursement ratios, please contact the local hospital pharmacy for detailed consultation. In addition, if you are looking for a more economical option, generic versions of avatrombopag are available in foreign markets, especially in Laos and Bangladesh. Their prices are relatively low, ranging from a few hundred to a thousand yuan. It is worth noting that these generic drugs are basically the same as the original drugs in terms of pharmaceutical ingredients.

Chronic idiopathic thrombocytopenia is an autoimmune disease in which the patient's immune system mistakenly attacks and destroys normal platelets, resulting in a low number of platelets and prone to bleeding and bruising. Avatrombopag promotes the production of platelets in the bone marrow by simulating the effect of TPO (thrombopoietin) in the body, thereby increasing platelet levels and reducing or preventing bleeding in patients.

Clinical trials have shown that avatrombopag shows good efficacy in increasing platelet levels and is more stable than traditional treatments such as corticosteroids or immunosuppressants. However, avatrombopag may also cause some side effects, such as headache, nausea, fatigue, etc., so the patient's response needs to be closely monitored when used and adjustments made as necessary.

In general, avatrombopag, as a new drug for the treatment of chronic idiopathic thrombocytopenia, provides patients with an effective and relatively safe treatment option, but it requires close monitoring and management by doctors during use to ensure maximum treatment effect and reduce the occurrence of side effects.